Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders. Its lead candidate, KB312, is a first-in-class, selective, immune-cell depleting monoclonal antibody which targets activated immune cells and aims to restore homeostasis through induction of immune tolerance. Kira Biotech has attracted venture capital funding and is progressing KB312 through preclinical development and phase 1 clinical trials with a team of drug development experts led by well-known US-based rheumatologist and immunologist, Dr Dan Baker.
Location: Australia, Queensland, Brisbane City
Employees: 1-10
Total raised: $20M
Founded date: 2019
Investors 3
| Date | Name | Website |
| - | IP Group A... | ipgroupanz... |
| 10.07.2026 | SPRIM Glob... | sprim.net |
| - | OneVenture... | one-ventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 31.10.2019 | Series A | $20M | IP Group N... |
Mentions in press and media 1
| Date | Title | Description |
| 31.10.2019 | Kira Biotech Raises A$20M in Series A Funding | Kira Biotech, a Brisbane, Australia-based immunology company, secured A$20m in Series A funding. The round was led by OneVentures, IP Group and the Advance Queensland Business Development Fund. The company intencds to use the funds to advan... |